TCT-415: Impact of Old Age on Clinical and Angiographic Characteristics of Coronary Artery Spasm as assessed by Acetylcholine Provocation test  by unknown
TUESDAY, NOVEMBER 8, 2011, 8:00 AM - 10:00 AM
TCT-415
Impact of Old Age on Clinical and Angiographic Characteristics of Coronary
Artery Spasm as assessed by Acetylcholine Provocation test
Woong Gil Choi1, Seung Woon Rha2, Byoung Geol Choi2, Amro Elnagar2, Sung Il
Im2, SunWon Kim2, Jin Oh Na2, Seong Woo Han2, Cheol Ung Choi2, Hong Euy Lim2,
Jin Won Kim2, Eung Ju Kim2, Chang Gyu Park2, Hong Seog Seo2, Dong Joo Oh2
1Konkuk University Chungju Hospital, Chungju, Republic of Korea; 2Korea
University Guro Hospital, Seoul, Republic of Korea
Background: Coronary artery spasm (CAS) is one of the important etiological factors
for patients (pts) with chest pain but no coronary artery stenosis. Generally smoking
and other factors were known the clinical risk factors for CAS. However, clinical
aspects related to age on CAS have been seldom investigated and reported. We
investigated whether there is any impact of old age on CAS and as compared with
younger age by intracoronary acetylcholine (Ach) provocation test.
Methods: A total 2954 consecutive pts without significant coronary artery lesion who
underwent Ach provocation test by injecting incremental doses of 20, 50, 100 ug into
the left coronary artery between March 2004 and April 2009 were enrolled. Significant
CAS was defined as focal or diffuse severe transient luminal narrowing (>70%)
with/without chest pain or ST-T change on ECG. the Ach provocation test results and
its associated parameters were compared between the younger pt group (<50 years old,
n=1044 pts, mean age; 41.13 ± 7.4 years) and older pt group (≥50 years old, n=1910
pts, mean age; 62.06 ± 7.44).
Results: Baseline clinical characteristics were similar between the two groups except
that more male (58.3% vs. 42.0%, p<0.001) and smoker (38.9% vs. 24.3%, p<0.001)
in younger patients group whereas more diabetes mellitus (16.3% vs. 6.0%, p<0.001),
dyslipidemia (21.3% vs. 13.1%, p<0.001) and hypertension (54.2% vs. 32.6%,
p<0.001) in older patients group. The rate of positive Ach provocation test was higher
in the older pts group. Further, older pts group showed higher incidence of diffuse and
multi-vessel spasm (Table).
Conclusion: In our study, we found that old age predisposes towards a higher chances
of significant CAS, diffuse and multivessel spasm as assessed with the intracoronary
Ach provocation test. Special care should be emphasized in older age pts present with
vasospastic angina.
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Background: The opening of the mitochondrial permeability transition pore (mPTP)
is a critical determinant of ischaemia-reperfusion injury, and the inhibition of its
opening confers powerful cardioprotection. Whether this cardioprotective effect is
present in the setting of hypertrophic cardiomyopathy (HCM) is investigated in this
study.
Methods: Human cardiomyocytes were isolated from left ventricular septal tissue,
harvested from patients undergoing surgical myectomy for obstructive HCM. The cells
were loaded with the fluorescent dye TMRM which localises to the mitochondria and
generates oxidative stress on confocal imaging. This results in mPTP opening indicated
by collapse of the mitochondrial membrane potential. Time taken to induce loss of
mitochondrial membrane potential was used as a measure of mPTP opening sensitivity.
Cells were randomised as follows: (1)DMSO 0.01% vehicle control (N=8/group)
(2)Cells pre-treated with ciclosporin-A (CsA)(0.2μM) for 15 mins (N=7/group)
(3)Cells pre-treated with atorvastatin(25μM)(N=7/group)
Results: In the control group mPTP opening was induced after 188.7±22.7 seconds of
oxidative stress, providing evidence for a functional mPTP in HCM. Furthermore, pre-
treatment with the known mPTP inhibitor, CsA, and atorvastatin, delayed the onset of
mPTP opening by 51±10% (P<0.001) and 35±7% (P<0.05), respectively.
Human cardiomyocyte with wave of depolarisation at left lower edge
Conclusion: For the first time in diseased human ventricular myocytes, we have
demonstrated that the mPTP is functional and that its opening can be inhibited by
cardioprotective agents such as CsA and atorvastatin.
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Atorvastatin, Administered at the Onset of Reperfusion, Protects Human
Myocardium Against Lethal Reperfusion Injury by Activation of the RISK
pathway
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Background: HMG Co-A reductase inhibitor (statin) therapy has been shown to reduce
peri-procedural event rates and myocardial injury in patients undergoing percutaneous
coronary intervention and cardiac surgery. In experimental animal models, treatment
with statins reduces myocardial infarct size by up-regulating enzymes of the
Reperfusion Injury Salvage Kinase (RISK) pathway. Whether this opportunity for
pharmacological cardioprotection exists in humans is unknown.
Methods: Right atrial appendages were harvested from consenting adult patients
undergoing elective cardiac surgery. From these, individual atrial trabeculae were
explanted. Trabeculae were then suspended in an organ bath and subjected to 90
minutes hypoxia followed by 120 minutes reoxygenation in order to simulate
ischaemia-reperfusion injury (IRI). At the end of the protocol, recovery of contractile
function was determined and compared to baseline. Trabeculae were randomised into
the following groups: Control (N=14); Hypoxic preconditioning (positive control)
(N=4); ATV (25μM) at reoxygenation (N=9); ATV & UO (10μM), an Erk1/2 inhibitor
(N=5); ATV & LY (15μM), a PI3K inhibitor (N=5); ATV & L-NAME (100μM), a non-
specific NOS inhibitor (N=7); ATV & 1400W (5μM), a specific inducible NOS
inhibitor (N=5); Inhibitors and vehicle agents alone had no effect on recovery (N=18).
Results: Trabeculae in the control group recovered 37.5±1.6% of baseline contractile
function following simulated IRI. Treatment with ATV at reperfusion significantly
improved recovery (61.1±3.8%, p<0.001). This effect was abolished by
LY(29.88±2.3%), UO(45.0±3.8%), L-NAME(34.35±4.0%) & 1400W(38.57±5.0%).
Conclusion: Atorvastatin, administered at reoxygenation, protects human atrial
myocardium from simulated ischaemia-reperfusion injury via activation of PI3-K, Erk
1/2 and NOS, components of the RISK pathway.
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Peri-adventitial Delivery of a Nanoparticle Albumin-Bound (nab) Rapamycin
Solution Reduces Luminal Stenosis in a Porcine Femoral Artery Balloon Injury
Model
Warren J Gasper1, Cynthia A Jimenez1, Kirk Seward2, Michael S Conte1, Christopher
D Owens1
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Background: Rapamycin-based drug delivery platforms in peripheral arteries have
proven to be safe and feasible but not effective in reducing intimal hyperplasia (IH).
We sought to determine whether periadventitial delivery of rapamycin would be
effective in reducing luminal stenosis in a porcine balloon injury model.
Methods: Femoral artery injury sites were created with a pressure-controlled
endothelial denudation. Two weeks later,a 20-30% overstretch of the injury sites was
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